San Antonio-based Phoenix Biotechnology, Inc. (PBI) has identified and developed a product extracted from Nerium oleander, a naturally occurring American plant. An active compound from this plant is called oleandrin. PBI’s research to date suggests that the extract prevents key viruses from correctly forming their protective “envelope”, rendering the virus progeny non-infective; the virus is then unable to overwhelm the host and its ability to spread itself is severely impaired. In this way, oleandrin may help “flatten the curve” and curtail the pandemic. Due to its efficacy against the viral envelope, it is considered a platform solution with wide-spectrum applicability to address multiple viral pathogens and their mutations.
Safety: A related PBI botanical extract (PBI-05204) has undergone Phase I and Phase II clinical trials for an oncology application. The same extract has been used to treat a significant number of patients. These trials established effective dosage and showed minimal side effects, even at the highest dose administered. PBI has also tested the extract against other viruses with similar enveloped structure at the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) at Ft. Detrick and other prestigious institutions.
The University of Texas Medical Branch (World Reference Center for Emerging Viruses and Arboviruses) in Galveston has performed a number of very successful laboratory experiments using the compound against COVID-19. Among the results was confirmation that oleandrin achieves a dramatic 20,000-fold reduction in viral infectivity within 24 hours.
Prophylaxis/Preventative Indications: Laboratory research at UTMB has shown indications of prophylaxis, as described in a newly published report that is currently undergoing peer-review. Animal trials designed to investigate the prevention as well as therapeutic efficacy of PBI’s botanical extract are also underway on COVID-19.
Phoenix Biotechnology seeks to help Americans and the citizenry of the wider world escape the grip of a virus that has ruined families, businesses, and communities globally.
After many months of a debilitating pandemic, with unprecedented power and resources at their disposal, the FDA has not approved or delivered a single drug, treatment, cure, remedy, other therapeutic, or vaccine.
With a compound that has already met FDA Phase I & II safety what could be the harm in allowing tests in a supervised hospital setting? Why such an apparently coordinated and hysterical media response?
• PBI’s extract successfully underwent Phase I and Phase II clinical trials in patients with cancer. Phase I trials were conducted at the University of Texas’ M.D. Anderson Cancer Center (Houston, TX) with Principal Investigator Dr. David Hong, MD. Phase II trials took place at 5 sites across the United States, under a team headed up by Dr. Jordan Berlin, MD (Vanderbilt University).
• Jagan Sastry, PhD, Professor at the M.D. Anderson Cancer Center, University of Texas, has shown that oleandrin as well as the PBI extract significantly reduces HIV virus infectivity through damage to the viral envelope, leaving virus progeny weak and ineffective. He also established that it inhibits HIV replication.
• In 2017, PBI’s extract proved successful in arresting other enveloped viruses, including Marburg and Ebola, under laboratory conditions in tests overseen by John M Dye, PhD, the Director of Virology at the U.S. Army Medical Research Institute of Infectious Diseases USAMRIID, Fort Detrick, Maryland. The presence of virally infected cells was eliminated within 48 hours.
• Dr. Ravit Boger, MD, Chief & Professor of Pediatrics and Infectious Disease at the Medical College of Wisconsin, has validated the PBI extract against Cytomegalovirus (CMV), HSV-1 ad HSV-2.
• Robert Harrod, PhD of the Department of Biological Sciences at Southern Methodist University, has worked with Dr. Newman to show that viral replication is inhibited for HTLV-1 via the same mechanism of envelope impairment.
• The PBI extract has also shown unique potential for glioblastoma and degenerative brain diseases such as Alzheimer’s and Traumatic Brain Injury (TBI). TBI has affected thousands of DoD personnel injured in the course of military operations.
• In late March-early April, the World Reference Center for Emerging Viruses and Arboviruses at the University of Texas Medical Branch in Galveston performed tests three times against COVID-19. The results affirmed that the active compound achieves a 20,000-fold reduction in viral infectivity. UTMB has continued to conduct laboratory testing with impressive results.